Ancora Heart Partners With Egnite to Accelerate CORCINCH-HF Trial Enrollment

April 19, 2023—Ancora Heart, Inc., which is developing a transcatheter device–based therapy to address heart failure (HF), and Egnite, Inc., a digital health company in the field of cardiovascular care, announced a strategic partnership to accelerate enrollment for the CORCINCH-HF pivotal clinical trial, which is evaluating the safety and efficacy of Ancora Heart’s AccuCinch ventricular restoration system.

The trial will use Egnite’s Trial Accelerator artificial intelligence (AI) technology to help identify eligible patients and drive enrollment for the pivotal trial. The AI solution with big data processing can automatically screen hundreds of thousands of patients against trial parameters to help identify more trial candidates without hospital staff dedicating hours to manual chart review, stated the company.

The Christ Health Network in Cincinnati, Ohio, is the first site in the CORCINCH-HF trial to utilize Egnite’s Trial Accelerator for enrollment.

Dean Kereiakes, MD, who is President of The Christ Hospital Heart and Vascular Institute and Coprincipal Investigator for CORCINCH-HF, commented in Ancora Heart’s press release, “Identifying patient candidates for clinical trial participation can be a complex task that requires many hours to review medical charts in the search for matching clinical criteria. The use of AI technology streamlines the trial screening process by identifying candidates more quickly and efficiently, thereby freeing up critical resources needed for clinical trial success.”

According to Ancora Heart, the investigational AccuCinch system is a completely transcatheter device designed to restore the structure and function of the enlarged left ventricle of the heart to address HF in patients with reduced ejection fraction.